25 results about "Weissella" patented technology

The invention relates to the technical field of probiotic development and utilization, in particular to a goose source Weissella cibaria F11 and application thereof. The Weissella cibarius F11 is preserved in the China General Microbiological Culture Collection Center on July 11, 2025, and the preservation number is CGMCC NO.35211. The Weissella cibarius F11 has the characteristics of good acid resistance and cholate resistance, and can be used for preparing the acid-resistant and cholate-resistant strain. And the bacillus subtilis has a good inhibition effect on pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and salmonella typhimurium, and also has stable acid production capacity and good safety. The Weissella sinus F11 provided by the invention meets the probiotic characteristic standard, the antibiotic resistance spectrum of the Weissella sinus F11 meets the feed probiotic safety standard, the growth of goslings can be remarkably promoted, the death rate and diarrhea occurrence rate of the goslings can be remarkably reduced, and the weissella sinus F11 can be used for preparing feed probiotics. The development potential in the fields of preparation of bacteriostatic and antibacterial drugs, probiotics for poultry feed, feed additives, poultry feed and the like is huge.

The invention relates to the technical field of microbial fermentation and food processing, and particularly discloses Weissella fusiformis JMF-006 as well as a mutagenesis method and application thereof. The invention provides a Weissella fusiformis JMF-006 with the exopolysaccharide yield of 20-25g / L. The Weissella fusiformis JMF-006 is obtained by breeding through a mutation breeding method of a high-yield EPS strain, and the mutation breeding method can also be used for culturing other high-yield EPS strains. The invention provides a strain composition, the strain composition comprises Weissella fusiformis JMF-006 or a high-yield EPS strain, other lactic acid bacteria strains (such as lactobacillus plantarum JMF-001 and lactobacillus casei JMF-002) can be further compounded, and the obtained strain composition has more excellent fermentation performance. When the Weissella fusiformis JMF-006, the high-yield EPS strain and the strain composition provided by the invention are applied to the fermentation process of food-derived drinks, a fermented product with stable properties and better flavor can be obtained, and the technical problems that the yield of extracellular polymeric substances is low, the fermentation performance is poor and the application range is narrow in an existing lactic acid bacteria starter are solved.

The invention relates to the technical field of microorganisms, in particular to Weissella fusiformis JWC120 with a function of inhibiting common harmful bacteria in animal breeding and application of the Weissella fusiformis JWC120. The Weissella fusiformis JWC120 with the function of inhibiting common harmful bacteria in animal breeding, provided by the invention, has the preservation number of CGMCC No.31945, and can effectively inhibit common escherichia coli, salmonella, staphylococcus aureus and shigella in animal breeding; a bacteriocin crude extract of the strain has a remarkable inhibition effect on common staphylococcus aureus in animal breeding, and has a good application prospect in animal disease prevention and treatment and development of livestock and poultry breeding health-care products.

This invention belongs to the field of microbial technology, specifically relating to a method for preparing and applying a fused Weissella extracellular polysaccharide. The extracellular polysaccharide of this invention is composed of glucose monosaccharide, and the glucose linkages include terminal glucose t-Glc(p), 1→4 linked glucose, 1→4,6 linked glucose, 1→3,6 linked glucose, and 1→2,6 linked glucose, with a relative molar ratio of (8~8.5):(1~1.2):(81~82):(7~7.5):(1~1.2):(0.5~1). It possesses excellent water-holding capacity, oil-holding capacity, emulsifying properties, and emulsion stability, and can be used as a highly efficient moisturizer, emulsifier, emulsion stabilizer, cosmetic additive, pharmaceutical additive, and food additive, showing broad application prospects in the food, cosmetic, and pharmaceutical fields.

This invention discloses *Wesleyanus esculenta* strain, its fermentation product filtrate, and its biological products, belonging to the field of cosmetic technology. This strain can be used in cosmetics, exhibiting excellent HAS inhibition ability and significant DPPH and ABTS free radical scavenging capabilities, achieving good antioxidant effects. Secondly, at various concentrations, its fermentation product filtrate can significantly downregulate the proportion of SA-β-Gal positive cells and significantly inhibit the gene expression of various matrix metalloproteinases, demonstrating a certain effect in reducing cellular aging markers. Furthermore, its fermentation product filtrate can inhibit tyrosinase activity in vitro and significantly inhibit melanin production in a zebrafish model, showing potential as a tyrosinase inhibitor or melanin production inhibitor. Its fermentation product filtrate can also significantly inhibit the secretion of the cellular inflammatory factor NO, exhibiting good soothing effects and a certain ability to regulate the skin microecology.

The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention relates to the technical field of microorganisms, and particularly discloses a Weissella fusiformis HTD7 and application thereof. The preservation number of the Weissella fusiformis HTD7 is CGMCC No.29775, the Weissella fusiformis HTD7 is good in antibacterial effect and different in color under different pH values, when the Weissella fusiformis HTD7 is applied to fermentation of high-fiber matrix cereals, the content of various beneficial components in a fermentation product can be increased, the product effect can be improved, when the Weissella fusiformis HTD7 is applied to preparation of bread and steamed buns, the product quality can be improved, and the Weissella fusiformis HTD7 can also be used as an edible dye, so that the Weissella fusiformis HTD7 can be used for The method can be widely applied to food preparation.

The application discloses a low-temperature rotting-promoting composite microbial inoculum, a high-efficiency in-situ straw returning method and application, and belongs to the technical field of microbial inoculums. The low-temperature rotting-promoting composite microbial inoculum comprises Stenotrophomonas maltophilia JGDQ29-2, Bacillus JX-7, Weissella covesi zqw90, Weissella paramesenteroides zqw26 and Neurospora crassa N7, and the mass ratio of the viable bacterial numbers of the Stenotrophomonas maltophilia JGDQ29-2, the Bacillus JX-7, the Weissella covesi zqw90, the Weissella paramesenteroides zqw26 and the Neurospora crassa N7 is 1-2:1-2:1-2:1.5-2:2.5-3. The application realizes the synchronous high-efficiency degradation of each component of the straw, improves the overall rotting efficiency and improves the soil nutrient components by screening high-efficiency cellulose, hemicellulose and lignin degradation strains and constructing a composite microbial system with multiple bacteria symbiosis and function complementation.

Disclosed are universal LAB test kits, assays, apparatus and compositions for detecting and quantifying Lactobacillus, Pediococcus and Weissella bacteria, or combinations thereof that contaminate biological materials such as fermentation mashes for production of ethanol from a crop such as corn. The assays can be performed on-site by ethanol technicians having limited laboratory experience and are based on quantitative PCR (qPCR) methods. Primers and probes are described that specifically hybridize to a LAB bacteria gene. Also disclosed are sample preparation methods and apparatus, including a filtration syringe (100) that can increase sensitivity of the assays up to about 1000-fold compared to traditional sample preparation methods.

The invention discloses Weissella sinus PD13 and application thereof in preparation of a product for treating or relieving Parkinson's disease, and belongs to the technical field of biological medicine. The Weissella sinus PD13 is preserved in the Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC No.65891. The Weissella sinus PD13 has the advantages that the Weissella Experiments prove that the Weissella sinus PD13 can be used for reducing the aggregation of alpha-Syn on the body wall of the PD model nematode NL5901; the movement ability of the NL5901 nematode is improved; the service life of the NL5901 nematode is prolonged; the fat content in the NL5901 nematode body is increased; the invention also finds that the Weissella sinus PD13 can reduce the oxidative stress level in the NL5901 nematode body. The Weissella sinus PD13 provided by the invention has a good treatment or alleviation effect on the Parkinson's disease, and a new way is provided for developing related drugs for treating or alleviating the Parkinson's disease.

The invention belongs to the technical field of biological medicines, and relates to application of Weissella sinus ZMC030 and exopolysaccharides thereof in prevention and treatment of toxic and side effects caused by chemotherapeutic drugs. The invention discovers that the Weissella cibaria ZMC030 exopolysaccharide can prevent, relieve or / and treat toxic and side effects caused by chemotherapeutic drugs for the first time; wherein the toxic and side effects of the heart comprise heart injury, myocardial cell apoptosis, cardiac fibrosis, heart tissue inflammation and the like; the intestinal toxic and side effects comprise intestinal injury, intestinal tissue structure disorder or / and intestinal mucosal barrier disorder, intestinal mucosal barrier permeability increase and intestinal flora disorder. Therefore, the Weissella cibaricola ZMC030 and the exopolysaccharide secreted by the Weissella cibaricola ZMC030 can be used for preparing products for preventing, relieving or / and treating cardiac toxic and side effects and intestinal toxic and side effects caused by chemotherapy drugs.

The present invention belongs to the field of biomedicine technology, and discloses a fusion of Weissella J1-1 and its application. The fusion Weissella J1-1 is deposited with CCTCC NO: M 20232334 and is deposited in the China Center for Type Culture Collection. The fusion Weissella J1-1 can secrete exopolysaccharide, and the exopolysaccharide secreted can significantly improve the lung function of mice with pulmonary fibrosis. It was found by observing lung tissue sections that it can also significantly improve lung tissue fibrosis, has no effect on the weight and growth status of mice, and has no damage to important organs, with high safety. In addition, cell experiments have found that exopolysaccharide can also significantly improve the expression of fibrosis-related genes in lung fibroblasts, and has no effect on the vitality of fibroblasts. Therefore, the present invention fusion Weissella J1-1 and the exopolysaccharide secreted by it can be used to prepare a drug for alleviating or / and treating pulmonary fibrosis.

The present invention relates to strains and compositions. The present invention provides a bacterial strain having at least 95% genetic homology with one or more bacterial strains selected from the group consisting of: Lactobacillus plantarum LB356R, preserved at DSM 33094; the invention relates to lactobacillus plantarum LB244R, which is preserved by DSM 32996. The invention discloses lactobacillus plantarum LB316R, which is preserved in DSM 33091. The lactobacillus plantarum LB312R is preserved in the form of DSM 33098; the lactobacillus casei LB113R is preserved in the form of DSM 32907; the lactobacillus casei LB116R is preserved in the form of DSM 32908, and the lactobacillus casei LB116R is preserved in the The enterococcus faecium LB276R is preserved in the form of DSM 32997; the leuconostoc mesenteroides LB349R is preserved in the form of DSM 33093; the invention relates to Weissella virida LB10G, which is preserved in the form of DSM 32906. The invention also provides compositions comprising the one or more bacterial strains.

The invention discloses Weissella virida and application of Weissella virida in the aspects of hangover alleviating, inflammation resisting, aging resisting, lipid lowering and liver protecting. According to the invention, a Weissella viridescens strain is obtained through screening, the Weissella viridescens strain is named as Weissella viridescens NP12, and the Weissella viridescens strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on October 23, 2025 in No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.36310. The Weissella viridescens strain is named as Weissella viridescens strain is named as Weissella viridescens. The strain NP12 has multiple effects of dispelling the effects of alcohol, reducing lipid, protecting the liver, resisting inflammation, resisting aging, regulating intestinal flora and the like, and can also be used for fermenting medicinal and edible traditional Chinese medicinal materials such as radix puerariae, and the total polyphenol content, the anti-inflammation activity, the anti-aging activity and the liver protection activity of an obtained fermentation product are obviously superior to those of unfermented radix puerariae, so that the strain NP12 or the fermentation product thereof can be used for developing multifunctional foods or medicines.

The invention provides Weissella cibaria, a Weissella cibaria and mulberry leaf co-fermentation product and application of the Weissella cibaria and mulberry leaf co-fermentation product in sugar and lipid reduction. The Weissella sinus (Weissella sp.) BYQ07 obtained through separation is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36500, and the preservation date is November 4, 2025. The Weissella sinus (Weissella sp.) BYQ07 has the advantages that the Weissella sinus (Weissella sp. The bacterium has various potential biological functions and metabolic pathways, such as carbon metabolism, nitrogen metabolism, energy generation and conversion and the like. The invention further provides a weissella cibaria BYQ07 and mulberry leaf co-fermented product, and the weissella cibaria BYQ07 and mulberry leaf co-fermented product is obtained by co-fermenting weissella cibaria BYQ07 and mulberry leaves. Researches discover that Weissella cibaria BYQ07 and a co-fermentation product of Weissella cibaria BYQ07 and mulberry leaves have obvious effects in the aspects of reducing blood sugar, reducing fat deposition, improving insulin resistance, improving liver functions, relieving liver fatty degeneration and the like, so that the Weissella cibaria BYQ07 has obvious effects in the aspect of developing products for reducing blood sugar, reducing blood fat, improving insulin resistance and improving liver functions. The important application value is realized.

Aiming at the current situation that probiotics are used for treating periodontitis in the prior art, the invention provides a strain of mixed Weissella confusa LHJY. The mixed Weissella confusa is named as a mixed Weissella confusa LHJY strain, and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20251930, and the preservation date is September 1, 2025. The method comprises the following steps: separating and purifying a pickled vegetable sample by an inventor to obtain probiotic mixed Weissella LHJY; a bacteriostatic experiment and a biological membrane removal experiment detect that the confused Weissella sp. LHJY has a remarkable inhibition effect on important periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum), and fills up the blank of application of the confused Weissella sp. To treatment of periodontitis in the prior art, and the confused Weissella sp. LHJY has a remarkable inhibition effect on the periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum). Moreover, the confused Weissella sp. LHJY can tolerate lysozyme with a relatively high concentration, effectively reduces the expression of inflammatory factors including interleukin 1 beta, tumor necrosis factor alpha and interleukin 6 in an inflammatory cell model, and has an important application prospect in the aspects of inhibiting periodontal disease pathogenic bacteria and regulating immune response.

In view of the current situation of probiotics for periodontitis treatment in the prior art, the application provides a Weissella confusa LHJY. The Weissella confusa LHJY strain is named as Weissella confusa LHJY strain, is preserved in the China Center for Type Culture Collection, and has a preservation number of CCTCC NO: M 20251930 and a preservation date of September 1, 2025. The inventors isolate and purify the probiotic Weissella confusa LHJY from a pickled vegetable sample; and find that the Weissella confusa LHJY has a significant inhibitory effect on P. gingivalis and F. nucleatum, which are important periodontal pathogenic bacteria, through a bacteriostatic experiment and a biofilm removal experiment, thereby filling the blank of application of the Weissella confusa to periodontitis treatment in the prior art. Moreover, the Weissella confusa LHJY can tolerate a high concentration of lysozyme, effectively reduces the expression of interleukin 1β, tumor necrosis factor α and interleukin 6 inflammatory factors in an inflammatory cell model, and has an important application prospect in inhibiting periodontal disease pathogenic bacteria and regulating immune responses.

The invention belongs to the technical field of screening and application of saccharomycetes, and particularly relates to a HM-02 and application of the HM-02 in shiny-leaved yellowhorn wheat-flavor baijiu, the HM-02 is adopted for fermenting shiny-leaved yellowhorn cakes, the fat content of shiny-leaved yellowhorn can be remarkably reduced, the antioxidant level in fermentation liquor is increased, and the viable count of the HM-02 is increased. The shiny-leaved yellowhorn cake fermentation liquor is added in the stacking link of the brewing process, and then the shiny-leaved yellowhorn wheat-flavor liquor can be prepared after fermentation in a pool, distillation, storage and blending. Results show that HM-02 in the shiny-leaved yellowhorn cake fermentation liquor can survive in the fermented grains, the abundance of the Gudiniberg's yeast and Weissella in the fermented grains is remarkably improved, the abundance of the acid-resistant lactic acid bacteria and the brewer's yeast is reduced, the content of aroma-producing components such as beta-phenethyl alcohol in the shiny-leaved yellowhorn wheat-flavor liquor is increased, and the content of 2, 4-dichlorophenethyl alcohol in the shiny-leaved yellowhorn wheat-flavor liquor is increased. Pleasant aroma components such as 1, 3-butanediol and methyl heptanoate are added; the content of bad flavor is reduced.

This invention belongs to the field of yeast screening and application technology, and particularly relates to a strain of *Saccharomyces cerevisiae* HM-02 and its application in *Xanthoceras sorbifolium* malt-flavored baijiu. This invention uses HM-02 to ferment *Xanthoceras sorbifolium* cake, which significantly reduces the fat content of *Xanthoceras sorbifolium* and increases the antioxidant level and viable count of HM-02 in the fermentation broth. By adding *Xanthoceras sorbifolium* cake fermentation broth during the stacking stage of the brewing process, followed by fermentation in tanks, distillation, storage, and blending, *Xanthoceras sorbifolium* malt-flavored baijiu can be prepared. Results show that HM-02 in the *Xanthoceras sorbifolium* cake fermentation broth can survive in the mash, significantly increasing the abundance of *Saccharomyces cerevisiae* and *Weissella* species in the mash, decreasing the abundance of acid-tolerant lactic acid bacteria and *Saccharomyces cerevisiae*, increasing the content of aroma components such as β-phenylethanol in the *Xanthoceras sorbifolium* malt-flavored baijiu, increasing pleasant aroma components such as 2,3-butanediol and methyl heptanoate, and reducing the content of undesirable flavors.

The invention relates to a Weissella cibaria strain with narrow-spectrum antibacterial activity, the Weissella cibaria strain is named Weissella cibaria B4, and is preserved in the Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC NO.65903, the preservation address is the 5th floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation date is February 18, 2025. The Weissella cibaria B4 can generate narrow-spectrum bacteriocin, has a remarkable bacteriostatic effect on various food-borne gram-negative pathogenic bacteria, but has no bacteriostatic effect on most gram-positive bacteria, so that the Weissella cibaria B4 can be used for targeted inhibition of growth of specific pathogenic bacteria, and has a broad application prospect. The method has good application value in the fields of biological medicine and food safety.

The present invention provides a composite microbial agent, a preparation method and application thereof, and relates to the technical field of composite microbial agents. The composite microbial agent of the present invention comprises, by weight, 3 to 6 parts of Lactobacillus plantarum, 3 to 6 parts of Pediococcus pentosaceus, 1 to 2 parts of Lactobacillus paracasei, 1 to 3 parts of Weissella mesenteroides, and 1 to 3 parts of Lactobacillus brevis. The composite microbial agent provided by the present invention has a fast growth rate and high acid production efficiency. Experiments in which the composite microbial agent provided by the present invention is used to prepare corncob silage show that the composite microbial agent can improve the smell, color and structure of corncob silage, reduce the crude fiber content and increase the crude fat content therein, and has a promoting effect on improving the quality of feed. The present invention verifies that adding corncob silage to the basic diet of pigs can improve the growth performance, slaughter performance and meat quality performance of pigs, reduce breeding costs and provide higher quality livestock products.

The invention discloses fused Weissella sp. Capable of improving the performance of soluble dietary fiber prebiotics in bean dregs and application of the fused Weissella sp. Capable of improving the performance of soluble dietary fiber prebiotics in bean dregs, the fused Weissella sp. Is Weissella sp. Pro131 and has been preserved in Guangdong Microbiological Culture Collection Center on August 14, 2025, and the preservation number of the fused Weissella sp. Pro131 is GDMCC No.66842. The fusion Weissella sp. Has the breakthrough that bean dregs can be directly converted into a high-activity prebiotic product through single strain fermentation, and the function is excellent. The fused Weissella is used for fermentation modification of the bean dregs, the content of soluble dietary fibers (SDF) of the bean dregs is increased by 1.8-3.2 times, and the bean dregs are synchronously endowed with excellent physicochemical and functional characteristics: the water holding capacity is increased by 1.1-1.4 times, the oil holding capacity is increased by 10%-30%, and the cholesterol adsorption capacity in a simulated intestinal environment is increased by 4.5-4.8 times, so that the fermented bean dregs SDF shows a stronger probiotic effect; and a scarce strain resource and an efficient solution are provided for functional food development.

The present invention relates to strains and compositions. The present invention provides a bacterial strain having at least 95% genetic homology with one or more bacterial strains selected from the group consisting of: Lactobacillus plantarum LB244R, preserved at DSM 32996; the invention relates to lactobacillus plantarum LB356R, which is preserved in DSM 33094. The invention discloses lactobacillus plantarum LB316R, which is preserved in DSM 33091. The lactobacillus plantarum LB312R is preserved in the form of DSM 33098; the lactobacillus casei LB113R is preserved in the form of DSM 32907; the lactobacillus casei LB116R is preserved in the form of DSM 32908, and the lactobacillus casei LB116R is preserved in the The enterococcus faecium LB276R is preserved in the form of DSM 32997; the leuconostoc mesenteroides LB349R is preserved in the form of DSM 33093; the invention relates to Weissella virida LB10G, which is preserved in the form of DSM 32906. The invention also provides compositions comprising the one or more bacterial strains.

The invention relates to the research on the capacity of three lactic acid bacteria with beneficial activity, namely, Weissella paramesenteroides, Lactococcus lactis and Lactococcus garview for resisting V.p AHPND (adenosine monophosphate-adenosine monophosphate-adenosine monophosphate), and particularly relates to the research on the capacity of the three lactic acid bacteria with beneficial activity, namely, Weissella paramesenteroides, Lactococcus lactis and Lactococcus garview for resisting V.p AHPND (adenosine monophosphate-adenosine monophosphate-adenosine monophosphate-adenosine monophosphate-adenosine monophosphate-adenosine monophosphate-adenosine monophosphate). Although the three lactic acid bacteria have no hemolytic activity, are sensitive to various antibiotics, and can tolerate various intestinal conditions (including pH 4-6, NaCl 1-2.5% and bile salt concentration 0.2-1.0%). However, compared with other two strains of lactic acid bacteria, the Weissella mesenteroides WP01 has the highest biological safety evaluation; the diameter of an inhibition zone can be obviously increased, the inhibition capability on other aquatic pathogenic bacteria is stronger, and the in-vitro AHPND inhibition effect of a single strain is superior to that of mixed bacteria. Besides, the abundance of AHPND in prawns can be remarkably reduced, the survival rate of prawns infected by AHPND can be remarkably increased, and it is found that the extracellular product IAA also has the capacity of inhibiting AHPND. Therefore, the Weissella mesenteroides WP01 is preserved in the China Center for Type Culture Collection, and the preservation number of the Weissella mesenteroides WP01 is CCTCC (China Center for Type Culture Collection) NO.M2025382.